Corus Pharma
Driving advancements in respiratory health with innovative inhalable treatments.
Driving advancements in respiratory health with innovative inhalable treatments.
Corus Pharma is a U.S.-based biotech and specialty drug company founded in 2001. The company focuses on advancing respiratory and infectious disease treatments through innovative inhalable therapies. Their product portfolio includes Corus 1020, an inhalable form of the antibiotic aztreonam for respiratory infections in cystic fibrosis patients, and Corus 1030, an inhaled lidocaine solution for severe persistent asthma. In April 2006, Corus Pharma received a significant $25.00MVenture Round investment from Gilead Sciences. Subsequently, on October 22, 2006, Gilead Sciences acquired Corus Pharma, signaling recognition of the company's potential and innovative approach in addressing severe respiratory conditions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $25.00M | 1 |
|
12 Apr 2006 |
| Series C | $65.00M | 9 |
|
13 Apr 2004 |
| Series B | $40.00M | - | 07 Mar 2003 | |
| Grant | $1.70M | - | 03 Oct 2002 | |
| Series A | $18.50M | - | 06 Jun 2001 |
No recent news or press coverage available for Corus Pharma.
We care about your data, and we'd love to use cookies make your experience better.
